NDA 219301 · Kalvista
Ekterly
Sebetralstat · Oral · Plasma Kallikrein Inhibitor
NovelOrphanCDER novel approval, Jul 3, 2025: To treat acute attacks of hereditary angioedema
Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 3, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
4 Phase 3, 1 recruiting
FAERS reports
539
191 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2026.
EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )
Mechanism: Sebetralstat is a competitive, reversible inhibitor of plasma kallikrein. Plasma kallikrein is a serine protease that cleaves high molecular weight kininogen (HK) releasing bradykinin which increases vascular permeability through activation of bradykinin receptors causing edema. Sebetralstat inhibits the cleavage of HK and reduces production of bradykinin, thereby treating the clinical symptoms of an acute, episodic attack of HAE. Sebetralstat also inhibits the positive feedback mechanism of the kallikrein kinin system by plasma kallikrein, thereby reducing factor XIIa and additional plasma...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EKTERLY · SEBETRALSTAT 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sebetralstat" as an intervention, any sponsor and status, largest first.
- An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)Pivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05505916 · 145 participants · Start Oct 24, 2022 · Primary completion May 27, 2026
Drug: KVD900 600 mg; KVD900 300 mg · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Little Rock, Arkansas; San Diego, California · 71 sites in all
- A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)Pivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05259917 · 136 participants · Start Feb 22, 2022 · Primary completion Dec 31, 2023
Drug: Placebo; KVD900 600 mg and 1 more · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 66 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT07654829 · 100 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: KVD900 600 mg · For: Hereditary Angioedema
Sites: Colorado Springs, Colorado
KalVista Pharmaceuticals, Ltd.Industry
NCT04208412 · 84 participants · Start Jul 2, 2019 · Primary completion Dec 8, 2020
Drug: KVD900 · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Centennial, Colorado; Chevy Chase, Maryland · 25 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT04349800 · 84 participants · Start Jan 4, 2018 · Primary completion Sep 10, 2018
Drug: KVD900; Placebo to KVD900 · For: Hereditary Angioedema
Sites: Wales, United Kingdom
- Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IIPivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT06467084 · 36 participants · Start Aug 1, 2024 · Primary completion Jan 15, 2026
Drug: KVD900 150 mg; KVD900 300 mg and 1 more · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 24 sites in all
- PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialPivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05511922 · 11 participants · Start Oct 24, 2022 · Primary completion May 27, 2026
Drug: KVD900 600 mg; Drug: KVD900 300 mg · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Little Rock, Arkansas; San Diego, California · 61 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema218
- drug ineffective102
- incorrect dose administered47
- headache36
- stress30
- product dose omission issue22
- weight increased22
- weight decreased19
- vomiting18
- nausea15
- off label use14
- dizziness13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 8 |
| 2025 | 82 |
| 2026 | 443 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
Riedl MA, Farkas H, Aygören-Pürsün E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Farkas H, Anderson J, Bouillet L, et al. · J Allergy Clin Immunol Pract 2025 · Multicenter Study, Clinical Trial, Phase III
- Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.
Craig T, Aygören-Pürsün E, Bernstein JA, et al. · Clin Exp Allergy 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Aygören-Pürsün E, Zanichelli A, Cohn DM, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.
Anderson J, Narsipur N, Jones D, et al. · Adv Ther 2026 · Comparative Study, Randomized Controlled Trial
- Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.
Tachdjian R, Narsipur N, Saharia P, et al. · Adv Ther 2026 · Systematic Review
Sponsor: Kalvista
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.